107 related articles for article (PubMed ID: 19818733)
21. Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma.
Zhang L; Sanderson SO; Lloyd RV; Smyrk TC
Am J Surg Pathol; 2007 Aug; 31(8):1191-5. PubMed ID: 17667542
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
23. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
Cao D; Ji H; Ronnett BM
Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
[TBL] [Abstract][Full Text] [Related]
24. Multifocal pancreatic ductal adenocarcinomas concomitant with intraductal papillary mucinous neoplasms of the pancreas detected by intraoperative pancreatic juice cytology. A case report.
Mori Y; Ohtsuka T; Tsutsumi K; Yasui T; Sadakari Y; Ueda J; Takahata S; Nakamura M; Tanaka M
JOP; 2010 Jul; 11(4):389-92. PubMed ID: 20601817
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic metastases of renal clear cell carcinoma: a clinicopathological study of 11 cases with special emphasis on the usefulness of PAX2 and mesothelin for the distinction from primary ductal adenocarcinoma of the pancreas.
Gnemmi V; Leroy X; Triboulet JP; Pruvot FR; Villers A; Leteurtre E; Buob D
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):157-62. PubMed ID: 24344503
[TBL] [Abstract][Full Text] [Related]
26. [Detection of hepatic micrometastasis in ductal pancreatic carcinoma by K-ras mutation analysis and determination of clinical relevance].
Bastian D; Gerdes B; Ramaswamy A; Tschammer C; Bartsch D
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):45-7. PubMed ID: 14518210
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
28. The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice.
Brembeck FH; Schreiber FS; Deramaudt TB; Craig L; Rhoades B; Swain G; Grippo P; Stoffers DA; Silberg DG; Rustgi AK
Cancer Res; 2003 May; 63(9):2005-9. PubMed ID: 12727809
[TBL] [Abstract][Full Text] [Related]
29. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
30. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
[TBL] [Abstract][Full Text] [Related]
31. BAG3 is a novel serum biomarker for pancreatic adenocarcinomas.
Falco A; Rosati A; Festa M; Basile A; De Marco M; d'Avenia M; Pascale M; Dal Piaz F; Tavano F; Di Mola FF; di Sebastiano P; Berloco PB; Nudo F; Caraglia M; Febbraro A; Barcaroli D; Scarpa A; Pezzilli R; De Laurenzi V; Turco MC
Am J Gastroenterol; 2013 Jul; 108(7):1178-80. PubMed ID: 23821002
[No Abstract] [Full Text] [Related]
32. Comparative analysis of K-ras point mutation, telomerase activity, and p53 overexpression in pancreatic tumours.
Uemura K; Hiyama E; Murakami Y; Kanehiro T; Ohge H; Sueda T; Yokoyama T
Oncol Rep; 2003; 10(2):277-83. PubMed ID: 12579258
[TBL] [Abstract][Full Text] [Related]
33. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
Segawa T; Hagiwara Y; Ishikawa K; Aoki N; Maeda M; Shiomi K; Hino O
Biochem Biophys Res Commun; 2008 May; 369(3):915-8. PubMed ID: 18328258
[TBL] [Abstract][Full Text] [Related]
34. [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats].
Liang S; Yang ZL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):109-13. PubMed ID: 17344598
[TBL] [Abstract][Full Text] [Related]
35. [Significance of detection of K-ras gene mutations and CA19-9 in serum for diagnosis of pancreatic carcinoma].
Zhang Y; Ji SR; Feng DX; Ji J; Han TQ
Ai Zheng; 2003 Mar; 22(3):295-7. PubMed ID: 12654190
[TBL] [Abstract][Full Text] [Related]
36. Cystic pancreatic endocrine tumor: a variant commonly confused with cystic adenocarcinoma.
Deshpande V; Lauwers GY
Cancer; 2007 Feb; 111(1):47-53. PubMed ID: 17173321
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic intraepithelial neoplasia and ductal adenocarcinoma induced by DMBA in mice.
Osvaldt AB; Wendt LR; Bersch VP; Backes AN; de Cássia A Schumacher R; Edelweiss MI; Rohde L
Surgery; 2006 Nov; 140(5):803-9. PubMed ID: 17084724
[TBL] [Abstract][Full Text] [Related]
38. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
40. Cystic ductal adenocarcinoma of pancreas: an unusual variant.
Gupta N; Krishnan PV; Muzaffar J; Arora A; Anuradha S; Gondal R; Agarwal A; Kar P
Trop Gastroenterol; 2006; 27(3):131-3. PubMed ID: 17310557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
